Cargando…

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

Immune checkpoint inhibitors (ICIs) have changed therapeutic algorithms in several malignancies, although intrinsic and secondary resistance is still an issue. In this context, the dysregulation of immuno-metabolism plays a leading role both in the tumor microenvironment (TME) and at the host level....

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannone, Gaia, Ghisoni, Eleonora, Genta, Sofia, Scotto, Giulia, Tuninetti, Valentina, Turinetto, Margherita, Valabrega, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352562/ https://www.ncbi.nlm.nih.gov/pubmed/32575899 http://dx.doi.org/10.3390/ijms21124414

Ejemplares similares

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
por: Giannone, Gaia, et al.
Publicado: (2019)

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
por: Turinetto, Margherita, et al.
Publicado: (2022)

Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
por: Scotto, Giulia, et al.
Publicado: (2021)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2020)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
por: Valabrega, Giorgio, et al.
Publicado: (2021)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Androgen receptor status predicts development of brain metastases in ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2017)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report
por: Zumstein, L., et al.
Publicado: (2023)

Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
por: Feng, Hai, et al.
Publicado: (2022)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Editorial: Immuno-Metabolism in Tumor Microenvironment
por: Prado-García, Heriberto, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
por: Nielsen, Tyler J., et al.
Publicado: (2021)

Radiotherapy as a New Player in Immuno-Oncology
por: Wang, Shang-Jui, et al.
Publicado: (2018)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

The Breast Tumor Microenvironment: A Key Player in Metastatic Spread
por: Terceiro, Lucas E. L., et al.
Publicado: (2021)

Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
por: Park, Kevin, et al.
Publicado: (2022)

Immunotherapies and Combination Strategies for Immuno-Oncology
por: Barbari, Cody, et al.
Publicado: (2020)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
por: Tramontana, Flavia, et al.
Publicado: (2021)

Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation
por: Zheng, Hongmei, et al.
Publicado: (2021)

The application of mechanobiotechnology for immuno-engineering and cancer immunotherapy
por: Yoon, Chi Woo, et al.
Publicado: (2022)

Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases
por: Roato, Ilaria, et al.
Publicado: (2018)

Is Immuno-modulation the Key to COVID-19 Pandemic?
por: Gupta, Ajay
Publicado: (2020)

Old Stars and New Players in the Brain Tumor Microenvironment
por: Parmigiani, Elena, et al.
Publicado: (2021)

Identification of RORg(+)T Cells as Key Players in Thyroid Autoimmunity From Checkpoint Immunotherapy
por: Lechner, Melissa G, et al.
Publicado: (2021)

YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
por: Kwiatkowska, Dominika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m9jld9u5esv1hb7il7k4thndm8